Evidence-based recommendations for successful Helicobacter pylori treatment

Expert Review of Gastroenterology and Hepatology

Volumn 8, Issue 1, 2014, Pages 21-28

  Wu, Jeng Yih ^a   Liou, Jyh Ming ^b   Graham, David Y ^c  

^a KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

amoxicillin; concomitant therapy; furazolidone; Helicobacter pylori; levofloxacin; metronidazole; prediction model; proton pump inhibitor; resistance; rifabutin; sequential therapy; susceptibility; therapy

Indexed keywords

AMOXICILLIN; ANTIBIOTIC AGENT; BISMUTH CITRATE; BISMUTH DERIVATIVE; BISMUTH SALICYLATE; CLARITHROMYCIN; FURAZOLIDONE; HELIDAC; LANSOPRAZOLE; METRONIDAZOLE; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFABUTIN; TETRACYCLINE; TINIDAZOLE;

ANTIBIOTIC RESISTANCE; BACTERIAL STRAIN; BEDTIME DOSAGE; CLINICAL PRACTICE; COMBINATION CHEMOTHERAPY; DRUG CHOICE; DRUG DOSE SEQUENCE; DRUG TREATMENT FAILURE; ERADICATION THERAPY; EVIDENCE BASED MEDICINE; HELICOBACTER INFECTION; HUMAN; NONHUMAN; PATIENT COMPLIANCE; PREDICTION; REVIEW; SALVAGE THERAPY;

AMOXICILLIN; ANTI-BACTERIAL AGENTS; BISMUTH; CLARITHROMYCIN; DRUG THERAPY, COMBINATION; EVIDENCE-BASED MEDICINE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; PROTON PUMP INHIBITORS; TREATMENT OUTCOME;

EID: 84893105411     PISSN: 17474124     EISSN: 17474132     Source Type: Journal    
DOI: 10.1586/17474124.2014.859522     Document Type: Review

References (29)

1. Malfertheiner P, Megraud F, O'Morain CA et al. Management of Helicobacter pylori infection-The Maastricht IV/Florence Consensus Report. Gut 61(5), 646-664 (2012
2. Megraud F, Coenen S, Versporten A et al. Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption. Gut 62(1), 34-42 (2013
3. Megraud F. Resistance of Helicobacter pylori to antibiotics and its impact on treatment options. Drug. Resist. Updat. 4(3), 178-186 (2001
4. Gisbert JP, Calvet X. Review article: The effectiveness of standard triple therapy for Helicobacter pylori has not changed over the last decade, but it is not good enough. Aliment. Pharmacol. Ther. 34(11-12), 1255-1268 (2011
5. Graham DY, Fischbach L. Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut 59(8), 1143-1153 (2010
6. Graham DY, Shiotani A. New concepts of resistance in the treatment of Helicobacter pylori infections. Nat. Clin. Pract. Gastroenterol. Hepatol. 5(6), 321-331 (2008
7. Megraud F. Current recommendations for Helicobacter pylori therapies in a world of evolving resistance. Gut Microbes 4(6) doi:10.4161/gmic.25930 (2013) (Epub ahead of print
8. McColl KE. Clinical practice. Helicobacter pylori infection. N. Engl. J. Med. 362(17), 1597-1604 (2010
9. Greenberg ER, Anderson GL, Morgan DR et al. 14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: A randomised trial. Lancet 378(9790), 507-514 (2011
10. Liou JM, Chen CC, Chen MJ et al. Sequential versus triple therapy for the first-line treatment of Helicobacter pylori: A multicentre, open-label, randomised trial. Lancet 381(9862), 205-213 (2013
11. Gisbert JP, Calvet X. Review article: Non-bismuth quadruple (concomitant) therapy for eradication of Helicobater pylori. Aliment. Pharmacol. Ther. 34(6), 604-617 (2011
12. Gisbert JP, Gisbert JL, Marcos S, Moreno-Otero R, Pajares JM. Third-line rescue therapy with levofloxacin is more effective than rifabutin rescue regimen after two Helicobacter pylori treatment failures. Aliment. Pharmacol. Ther. 24(10), 1469-1474 (2006
13. Gisbert JP, Gisbert JL, Marcos S, Moreno-Otero R, Pajares JM. Levofloxacin-vs. ranitidine bismuth citrate-containing therapy after Helicobacter pylori treatment failure. Helicobacter 12(1), 68-73 (2007
14. Graham DY, Lee YC, Wu MS. Rational Helicobacter pylori therapy: Evidence-based medicine rather than medicine-based evidence. Clin. Gastroenterol. Hepatol. doi:10.1016/j.cgh.2013.05.028 (2013) (Epub ahead of print
15. Malfertheiner P, Megraud F, O'Morain C et al. Current concepts in the management of Helicobacter pylori infection: The Maastricht III Consensus Report. Gut 56(6), 772-781 (2007
16. Malfertheiner P, Megraud F, O'Morain C et al. Current European concepts in the management of Helicobacter pylori infection-The Maastricht Consensus Report. The European Helicobacter pylori Study Group (EHPSG). Eur. J. Gastroenterol. Hepatol. 9(1), 1-2 (1997
17. Fuccio L, Minardi ME, Zagari RM, Grilli D, Magrini N, Bazzoli F. Metaanalysis: Duration of first-line proton-pump inhibitor based triple therapy for Helicobacter pylori eradication. Ann. Intern. Med. 147(8), 553-562 (2007
18. Rimbara E, Fischbach LA, Graham DY. Optimal therapy for Helicobacter pylori infections. Nat. Rev. Gastroenterol. Hepatol. 8(2), 79-88 (2011
19. Graham DY. Efficient identification and evaluation of effective Helicobacter pylori therapies. Clin. Gastroenterol. Hepatol. 7(2), 145-148 (2009
20. Furuta K, Adachi K, Ohara S et al. Relationship between the acid-inhibitory effects of two proton pump inhibitors and CYP2C19 genotype in Japanese subjects: A randomized two-way crossover study. J. Int. Med. Res. 38(4), 1473-1483 (2010
21. Osato MS, Reddy R, Reddy SG, Penland RL, Graham DY. Comparison of the Etest and the NCCLS-Approved agar dilution method to detect metronidazole and clarithromycin resistant Helicobacter pylori. Int. J. Antimicrob. Agents 17(1), 39-44 (2001
22. Lu H, Zhang W, Graham DY. Bismuth-containing quadruple therapy for Helicobacter pylori: Lessons from China. Eur. J. Gastroenterol. Hepatol. 25(10), 1134-1140 (2013
23. Liang X, Xu X, Zheng Q et al. Efficacy of Bismuth-containing quadruple therapies for clarithromycin-, metronidazole-, and fluoroquinolone-resistant Helicobacter pylori infections in a prospective study. Clin. Gastroenterol. Hepatol. 11(7), 802-807 (2013
24. Dore MP, Farina V, Cuccu M, Mameli L, Massarelli G, Graham DY. Twice-A-day bismuth-containing quadruple therapy for Helicobacter pylori eradication: A randomized trial of 10 and 14 days. Helicobacter 16(4), 295-300 (2011
25. Dore MP, Graham DY, Mele R et al. Colloidal bismuth subcitrate-based twice-A-day quadruple therapy as primary or salvage therapy for Helicobacter pylori infection. Am. J. Gastroenterol. 97(4), 857-60 (2002
26. Graham DY, Lu H. Furazolidone in Helicobacter pylori therapy: Misunderstood and often unfairly maligned drug told in a story of French bread. Saudi. J. Gastroenterol. 18(1), 1-2 (2012
27. Borody TJ, Pang G, Wettstein AR et al. Efficacy and safety of rifabutin-containing rescue therapy' for resistant Helicobacter pylori infection. Aliment. Pharmacol. Ther. 23(4), 481-488 (2006
28. Furuta T, Sugimoto M, Kodaira C et al. The dual therapy with 4 times daily dosing of rabeprazole and amoxicillin as the 3rd rescue regimen for eradication of Helicobacter pylori. Hepatogastroenterology 57(102-103), 1314-1319 (2010
29. Suzuki H, Nishizawa T, Muraoka H, Hibi T. Sitafloxacin and garenoxacin may overcome the antibiotic resistance of Helicobacter pylori with gyrA mutation. Antimicrob. Agents Chemother. 53(4), 1720-1721 (2009